Viquglip-DM
Description_Effects
Viquglip-DM is a comprehensive antidiabetic formulation that combines Dapagliflozin, Metformin, and Vildagliptin to provide effective control of type 2 diabetes mellitus. Each component works through a unique mechanism to target different aspects of blood sugar regulation. Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose levels by enhancing urinary glucose excretion, thus helping to remove excess sugar from the body. Vildagliptin, a DPP-4 inhibitor, boosts natural incretin hormones, which promote insulin release and reduce glucose production by the liver, especially after meals. Metformin, a well-established biguanide, reduces glucose absorption from food, suppresses hepatic glucose production, and enhances insulin sensitivity in the muscles and tissues. This triple-drug combination delivers synergistic benefits by addressing the root causes of elevated blood glucose—offering better glycemic control than individual agents alone. Regular use of Viquglip-DM helps reduce the risk of long-term diabetic complications such as kidney disease, neuropathy, retinopathy, and cardiovascular conditions. Viquglip-DM should be used under medical supervision, along with a healthy lifestyle, balanced diet, and regular exercise. Continued use can significantly improve quality of life and long-term health outcomes in patients with type 2 diabetes.
